Patents Assigned to University of California, San Diego
-
Patent number: 12280349Abstract: In various embodiments, the present invention is directed to a facile one-pot reverse emulsion process to assemble core-shell nanoparticles (CS-SMNPs) into bright and noniridescent photonic supraballs. In one or more embodiments, the present invention is directed to core-shell nanoparticles having an inner high refractive index (RI) core and an outer low RI shell. In one or more embodiment, the present invention includes core-shell nanoparticles using high RI (˜1.74) melanin cores and low-RI (˜1.45) silica shells. In various embodiments, these nanoparticles may be self-assembled into bright and noniridescent supraballs using a scalable one-pot reverse emulsion process. According to various embodiments of the present invention, it is possible to generate a full spectrum of structural colors with the combination of only two ingredients, synthetic melanin and silica.Type: GrantFiled: September 13, 2022Date of Patent: April 22, 2025Assignees: The University of Akron, University of California, San DiegoInventors: Ali Dhinojwala, Ming Xiao, Ziying Hu, Matthew Shawkey, Nathan Gianneschi
-
Publication number: 20210011103Abstract: A magnetic resonance imaging apparatus according to an embodiment includes sequence controlling circuitry and processing circuitry. The sequence controlling circuitry acquires a first piece of data by executing a first pulse sequence having a first Echo Time (TE) value, to acquire a second piece of data by executing a second pulse sequence having a second TE value different from the first TE value, and to acquire a third piece of data by executing a third pulse sequence having a third TE value different from the first and the second TE values. The processing circuitry extracts a signal related to water, a signal related to a first fat, and a signal related to a second fat, on the basis of the first piece of data, the second piece of data, and the third piece of data.Type: ApplicationFiled: July 8, 2019Publication date: January 14, 2021Applicants: University of California, San DiegoInventors: Mitsue MIYAZAKI, Christine CHUNG
-
Patent number: 8741883Abstract: The invention is in general directed to compounds and methods for diagnosing, preventing or alleviating the symptoms of amyloid-associated diseases, for example, neuronal diseases, such as, for example, Alzheimer's disease, methods of screening for compounds useful in preventing or alleviating the symptoms of amyloid-associated diseases, methods of diagnostic imaging of A-beta fibrils, and compounds and methods useful for studying normal or disease-associated cellular mechanisms relating to amyloid proteins.Type: GrantFiled: January 13, 2010Date of Patent: June 3, 2014Assignee: The Regents of the University of California—San DiegoInventors: Jerry Yang, Petra Inbar
-
Patent number: 8484146Abstract: The present invention provides an interaction device adapted for setting own controller for maximizing expectation of information defined between a hypothesis about an interaction object and own input/output. Thus, the social robot can judge by using only simple input/output sensor whether or not the human being is present or absent at the outside world.Type: GrantFiled: January 17, 2007Date of Patent: July 9, 2013Assignees: Sony Corporation, University of California, San Diego Regents of University of CaliforniaInventors: Javier R. Movellan, Fumihide Tanaka
-
Publication number: 20120148660Abstract: The invention provides TLR agonists and conjugates thereof useful in vaccines and to prevent, inhibit or treat a variety of disorders including pathogen infection and asthma.Type: ApplicationFiled: February 7, 2008Publication date: June 14, 2012Applicant: Regents of the University of California, San Diego UCSD Technology Transfer OfficeInventors: Dennis A. Carson, Howard B. Cottam, Wolfgang Wrasidlo, Christina C.N. Wu, Gregory A. Daniels
-
Publication number: 20120041032Abstract: The present invention relates to metalloprotein inhibitors comprising: a. an organic substituent and at least one zinc binding group (ZBG) covalently attached thereto; or b. a ZBG substituted by a side chain wherein the ZBG is of formula (I): wherein X is O or S and each R1, R2, R3, and R4 is individually hydrogen or an organic radical. The metalloprotein inhibitors are useful for preventing or treating a pathological disease, condition, or symptom that is associated with pathological metalloprotein activity and/or that is alleviated by inhibition of said activity.Type: ApplicationFiled: August 15, 2011Publication date: February 16, 2012Applicant: The Regents of the University of California, San DiegoInventors: David T. Puerta, Seth M. Cohen, Jana A. Lewis
-
Publication number: 20120028905Abstract: Novel antiproliferative compounds, compositions comprising the same, and methods of use thereof are disclosed.Type: ApplicationFiled: October 11, 2011Publication date: February 2, 2012Applicants: Smithsonian Tropical Research Institute, University of California, San Diego, Oregon StateInventors: Kerry Leigh McPhail, Rebecca Ann Medina, William Henry Gerwick, Douglas Eugene Goeger, Todd Leo Capson
-
Patent number: 7862807Abstract: Transport molecules include a dendrimer and a biologically active molecule. The dendrimer of such transport molecules includes at least one guanidine group, at least one protonated guanidine group, at least one protected guanidine group, at least one amidine group, at least one protonated amidine group, at least one protected amidine group, at least one ureido group, at least one protonated ureido group, at least one protected ureido group, at least one thioureido group, at least one protonated thioureido group, or at least one protected thioureido group. The biologically active molecule is bonded to the dendrimer. A method of increasing the bioavailability of a drug includes bonding the drug to a dendrimer of the invention.Type: GrantFiled: July 18, 2003Date of Patent: January 4, 2011Assignee: University of California, San DiegoInventors: Murray Goodman, Churl Min Seong, Guido Harms
-
Publication number: 20100210598Abstract: Provided herein are small molecule conjugates that are agonists or antagonists of one or more toll-like receptors.Type: ApplicationFiled: February 11, 2010Publication date: August 19, 2010Applicant: Regents of the University of California, San DiegoInventors: Dennis A. Carson, Howard B. Cottam, Tomoko Hayashi, Michael Chan
-
Patent number: 7624076Abstract: A facial expression recognition system that uses a face detection apparatus realizing efficient learning and high-speed detection processing based on ensemble learning when detecting an area representing a detection target and that is robust against shifts of face position included in images and capable of highly accurate expression recognition, and a learning method for the system, are provided. When learning data to be used by the face detection apparatus by Adaboost, processing to select high-performance weak hypotheses from all weak hypotheses, then generate new weak hypotheses from these high-performance weak hypotheses on the basis of statistical characteristics, and select one weak hypothesis having the highest discrimination performance from these weak hypotheses, is repeated to sequentially generate a weak hypothesis, and a final hypothesis is thus acquired.Type: GrantFiled: March 7, 2008Date of Patent: November 24, 2009Assignees: Sony Corporation, University of California, San DiegoInventors: Javier R. Movellan, Marian S. Bartlett, Gwendolen C. Littlewort, John Hershey, Ian R. Fasel, Eric C. Carlson, Josh Susskind, Kohtaro Sabe, Kenta Kawamoto, Kenichi Hidai
-
Publication number: 20090286987Abstract: The present invention relates to metalloprotein inhibitors comprising: a. an organic substituent and at least one zinc binding group (ZBG) covalently attached thereto; or b. a ZBG substituted by a side chain wherein the ZBG is of formula (I): wherein X is O or S and each R1, R2, R3, and R4 is individually hydrogen or an organic radical. The metalloprotein inhibitors are useful for preventing or treating a pathological disease, condition, or symptom that is associated with pathological metalloprotein activity and/or that is alleviated by inhibition of said activity.Type: ApplicationFiled: July 15, 2009Publication date: November 19, 2009Applicant: Regents of the University of California, San Diego UCSD Technology Transfer OfficeInventors: David T. Puerta, Seth M. Cohen, Jana A. Lewis
-
Patent number: 7579486Abstract: The present invention relates to metalloprotein inhibitors comprising: a. an organic substituent and at least one zinc binding group (ZBG) covalently attached thereto; or b. a ZBG substituted by a side chain wherein the ZBG is of formula (I): wherein X is O or S and each R1, R2, R3, and R4 is individually hydrogen or an organic radical. The metalloprotein inhibitors are useful for preventing or treating a pathological disease, condition, or symptom that is associated with pathological metalloprotein activity and/or that is alleviated by inhibition of said activity.Type: GrantFiled: October 30, 2006Date of Patent: August 25, 2009Assignee: Regents of the University of California, San DiegoInventors: David T. Puerta, Seth M. Cohen, Jana A. Lewis
-
Publication number: 20090191275Abstract: Provided herein are methods for preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.Type: ApplicationFiled: November 12, 2008Publication date: July 30, 2009Applicant: The Regents of the University of California, San DiegoInventors: Ranjan Dohil, John Bastian, Seema Aceves, Elaine Phillips, Malcolm Hill
-
Publication number: 20090181099Abstract: Provided herein are methods for preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.Type: ApplicationFiled: November 12, 2008Publication date: July 16, 2009Applicant: The Regents of the University of California, San DiegoInventors: Ranjan DOHIL, John BASTIAN, Seema ACEVES, Elaine PHILLIPS, Malcolm HILL
-
Publication number: 20080285835Abstract: Systems and techniques for reducing distortions in magnetic resonance images. In one aspect, machine-implemented method for reducing image distortion in magnetic resonance imaging (MRI) includes receiving a first MRI image and a second MRI image, estimating displacements of voxels between the first MRI image and the second MRI image by minimizing a cost function expressing a cost of the displacements, reducing distortion in an MRI image using the estimated displacements, and making the MRI image having reduced distortion available. The first MRI image and the second MRI image were acquired using different gradient fields.Type: ApplicationFiled: May 16, 2008Publication date: November 20, 2008Applicant: University of California, San DiegoInventors: Dominic Holland, Anders Dale
-
Publication number: 20080188641Abstract: The present invention provides methods for reducing or inhibiting angiogenesis in a tissue, by contacting ?5?1 integrin in the tissue with an agent that interferes with specific binding of the ?5?1 integrin to a ligand expressed in the tissue; and methods of identifying angiogenesis in a tissue, by contacting the tissue with an agent that specifically binds ?5?1 integrin, and detecting specific binding of the agent to ?5?1 integrin associated with a blood vessel in the tissue. Also provided are methods of diagnosing a pathological condition characterized by angiogenesis in a tissue in an individual.Type: ApplicationFiled: May 1, 2007Publication date: August 7, 2008Applicant: University of California San DiegoInventor: Judith A. Varner
-
Publication number: 20080161362Abstract: The present invention relates to metalloprotein inhibitors comprising: a. an organic substituent and at least one zinc binding group (ZBG) covalently attached thereto; or b. a ZBG substituted by a side chain wherein the ZBG is of formula (I): wherein X is O or S and each R1, R2, R3, and R4 is individually hydrogen or an organic radical. The metalloprotein inhibitors are useful for preventing or treating a pathological disease, condition, or symptom that is associated with pathological metalloprotein activity and/or that is alleviated by inhibition of said activity.Type: ApplicationFiled: April 28, 2005Publication date: July 3, 2008Applicant: Regents of the University of California, San Diego UCSD Technology transfer officeInventors: David T. Puerta, Seth M. Cohen, Jana A. Lewis
-
Publication number: 20070275367Abstract: This invention provides a class of binding proteins with a range of binding specificities and affinities based upon variation at select amino acid positions within a scaffold. The variable positions may be readily modified to produce a library of binding proteins with different binding specificities and affinities. The library may be screened to identify one or more as binding a ligand of interest. Compositions comprising the binding proteins, as well as methods of using the binding proteins are also provided.Type: ApplicationFiled: December 31, 2004Publication date: November 29, 2007Applicant: University of California, San DiegoInventors: Partho Ghosh, Stephen McMahon, Jason Miller, Jeffrey Lawton
-
Patent number: 7199285Abstract: The present invention provides methods of modulating abscisic acid signal transduction in plants. The method comprise introducing into the plant a recombinant expression cassette comprising a promoter operably linked to an ABH1 polynucleotide.Type: GrantFiled: December 18, 2003Date of Patent: April 3, 2007Assignee: University of California, San DiegoInventors: Julian Schroeder, Veronique Hugouvieux, June M. Kwak
-
Patent number: 7157623Abstract: The invention provides a fertile transgenic monocot, e.g., maize, plant encoding an endosperm specific prolamin box binding factor peptide (PBF) that is expressed so as to increase the methionine and/or lysine content of the seeds of said plant over said content in the seeds of the corresponding plant that lacks said gene, wherein said corresponding plant was used to prepare said transgenic plant, or an ancestor of said transgenic plant.Type: GrantFiled: July 3, 2002Date of Patent: January 2, 2007Assignee: Regents of the University of California, San DiegoInventors: Robert J. Schmidt, Stephen P. Moose, Jesus Vicente-Carbajosa